



W229 N1870 Westwood Drive
Waukesha, WI 53186, USA
Phone: +1-262-574-5074
Fax: +1-262-574-0703
Email: info@coppehealth.com
Web: www.coppelabs.com

May 28th, 2020
Waukesha, Wisconsin, USA

Coppe Healthcare Solutions (Coppe Laboratories), a CLIA Certified Laboratory based in Waukesha, Wisconsin, has completed a Joint Venture agreement with Open CoVIDx, a CLIA certified Laboratory based in San Francisco Bay area of California.

The Joint Venture will be called Coppe-Open CoVIDx Laboratories, and will combine the laboratory capacities of the two for a total of 1.5 Million COVID-19 diagnostic tests per month, by end of June 2020. The increased capacity will put the venture among the top 5 COVID-19 testing Laboratories in the United States.

The Coppe-Open CoVIDx Laboratories will provide employers in the USA and Kenya with COVID-19 diagnostic testing for employees, environmental testing of work places, and antibody testing within the FDA approved guidelines.

About Coppe – www.coppelabs.com

Coppe is a Wisconsin-based CLIA-certified laboratory focused on infectious diseases testing. The CEO of Coppe Laboratories is Dr. Konstance Knox, the virologist who previously co-founded what is now Viracor-Eurofins in 2000. Dr. Knox has expanded Coppe's testing footprint to serve 1,000 Doctor's Offices in the United States, and internationally with a Coppe run Laboratory at the new 5,000 bed Hamptons Hospital, under development at Mwale Medical and Technology City (MMTC) in Kenya.

About Open CoVIDx – www.opencovidx.org

Open CoVIDx is a San Francisco Bay Area CLIA-certified lab focused on large scale SARS-CoV-2 (COVID-19) testing through laboratory automation and innovative use of biotechnologies. Open CoVIDx was formed from partnerships with OpenTrons (www.opentrons.com) and multiple laboratory test vendors serving national and international clients.

For media inquiries please email info@coppehealth.com

+1 262.574.5074

www.coppelabs.com

Sincerely,

A handwritten signature in black ink that reads "Konstance Knox".

Dr. Konstance Knox, PhD
CEO, Coppe Laboratories